Northwest Biotherapeutics Stock Analysis
| NWBO Stock | USD 0.27 0.01 3.85% |
Northwest Biotherapeutics is overvalued with Real Value of 0.23 and Hype Value of 0.27. The main objective of Northwest Biotherapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Northwest Biotherapeutics is worth, separate from its market price. There are two main types of Northwest Biotherapeutics' stock analysis: fundamental analysis and technical analysis.
The Northwest Biotherapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Northwest |
Northwest OTC Stock Analysis Notes
The company recorded a loss per share of 0.06. Northwest Biotherapeutics had not issued any dividends in recent years. The entity had 1:16 split on the 26th of September 2012. Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.The quote for Northwest Biotherapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Northwest Biotherapeutics contact Linda JD at 240 497-9024 or learn more at www.nwbio.com.Northwest Biotherapeutics Investment Alerts
| Northwest Biotherapeutics generated a negative expected return over the last 90 days | |
| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics has high historical volatility and very poor performance | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Northwest Biotherapeutics Upcoming and Recent Events
Earnings reports are used by Northwest Biotherapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Northwest Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 705.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Northwest Biotherapeutics's market, we take the total number of its shares issued and multiply it by Northwest Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Northwest Profitablity
Northwest Biotherapeutics' profitability indicators refer to fundamental financial ratios that showcase Northwest Biotherapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Northwest Biotherapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Northwest Biotherapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Northwest Biotherapeutics' profitability requires more research than a typical breakdown of Northwest Biotherapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 52.11 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (54.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $54.95. Technical Drivers
As of the 27th of December, Northwest Biotherapeutics secures the Standard Deviation of 4.11, mean deviation of 2.98, and Risk Adjusted Performance of (0.04). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Northwest Biotherapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed thirteen technical drivers for Northwest Biotherapeutics, which can be compared to its peers in the industry.Northwest Biotherapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Northwest Biotherapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Northwest Biotherapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Northwest Biotherapeutics Outstanding Bonds
Northwest Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Northwest Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Northwest bonds can be classified according to their maturity, which is the date when Northwest Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Northwest Biotherapeutics Predictive Daily Indicators
Northwest Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Northwest Biotherapeutics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 201784.0 | |||
| Daily Balance Of Power | 0.5 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 0.27 | |||
| Day Typical Price | 0.27 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.01 |
Northwest Biotherapeutics Forecast Models
Northwest Biotherapeutics' time-series forecasting models are one of many Northwest Biotherapeutics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Northwest Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Northwest OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Northwest Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Northwest shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Northwest Biotherapeutics. By using and applying Northwest OTC Stock analysis, traders can create a robust methodology for identifying Northwest entry and exit points for their positions.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Northwest Biotherapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.